CN103908542A - 一种治疗类风湿性关节炎的复方制剂及其制备方法 - Google Patents
一种治疗类风湿性关节炎的复方制剂及其制备方法 Download PDFInfo
- Publication number
- CN103908542A CN103908542A CN201410180064.4A CN201410180064A CN103908542A CN 103908542 A CN103908542 A CN 103908542A CN 201410180064 A CN201410180064 A CN 201410180064A CN 103908542 A CN103908542 A CN 103908542A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- rheumatoid arthritis
- preparation
- fici pumilae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 title claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 16
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 14
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 14
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 14
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 14
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960001929 meloxicam Drugs 0.000 claims abstract description 12
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims abstract description 9
- 229940082787 spirulina Drugs 0.000 claims abstract description 7
- 239000000284 extract Substances 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims abstract description 6
- 238000010992 reflux Methods 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 241000725145 Homalomena Species 0.000 claims description 7
- 241000581682 Sanguisorba Species 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 241000596154 Belamcanda Species 0.000 abstract 2
- 241000218691 Cupressaceae Species 0.000 abstract 2
- 240000002373 Ficus pumila Species 0.000 abstract 2
- 235000006718 Ficus pumila Nutrition 0.000 abstract 2
- 241000123866 Homalomena occulta Species 0.000 abstract 2
- 240000004064 Poterium sanguisorba Species 0.000 abstract 2
- 235000008291 Poterium sanguisorba Nutrition 0.000 abstract 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 2
- 240000001341 Reynoutria japonica Species 0.000 abstract 2
- 241000316658 Sauromatum giganteum Species 0.000 abstract 2
- 239000002775 capsule Substances 0.000 abstract 2
- 238000002156 mixing Methods 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 1
- 238000011049 filling Methods 0.000 abstract 1
- 238000003801 milling Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 15
- 208000006820 Arthralgia Diseases 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 238000004062 sedimentation Methods 0.000 description 7
- 230000008961 swelling Effects 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 229960001639 penicillamine Drugs 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- -1 isobutyl phenylpropyl Chemical group 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 102000004020 Oxygenases Human genes 0.000 description 1
- 108090000417 Oxygenases Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 239000009395 Zhengqing Fengtongning Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410180064.4A CN103908542B (zh) | 2014-04-30 | 2014-04-30 | 一种治疗类风湿性关节炎的复方制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410180064.4A CN103908542B (zh) | 2014-04-30 | 2014-04-30 | 一种治疗类风湿性关节炎的复方制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103908542A true CN103908542A (zh) | 2014-07-09 |
CN103908542B CN103908542B (zh) | 2016-11-23 |
Family
ID=51034746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410180064.4A Expired - Fee Related CN103908542B (zh) | 2014-04-30 | 2014-04-30 | 一种治疗类风湿性关节炎的复方制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103908542B (zh) |
-
2014
- 2014-04-30 CN CN201410180064.4A patent/CN103908542B/zh not_active Expired - Fee Related
Non-Patent Citations (5)
Title |
---|
朱春来等: "甲氨蝶呤和硫酸软骨素联合雷公藤小剂量治疗类风湿关节炎临床疗效观察", 《中国社区医师 医学专业》 * |
王宗怡: "类风湿关节炎四大主症用药体会", 《山东中医杂志》 * |
童知秋主编: "《中医文化与养生. 下》", 30 June 2010, 远方出版社 * |
雷静等: "Ⅱ型胶原注射骨关节炎时C-反应蛋白及类风湿因子的表达", 《中国组织工程研究》 * |
马国刚著: "《野生食用植物资源与健康营养》", 31 May 2011, 知识产权出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN103908542B (zh) | 2016-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105535715A (zh) | 治疗湿热内蕴型湿疹的中药外洗液 | |
CN101032593A (zh) | 一种治疗痤疮的中药制剂 | |
CN103182019A (zh) | 治疗复发性口腔溃疡的中药组合物 | |
CN104491052A (zh) | 治疗风湿及类风湿性关节炎的中药组合物及其制备方法 | |
CN101856481A (zh) | 一种消肿散结的外用膏剂 | |
CN104491220A (zh) | 一种治疗带状疱疹的中药组合物 | |
CN103100003B (zh) | 一种治疗急性痛风性关节炎的中药组合物 | |
CN102764360B (zh) | 一种治疗急性膀胱炎的中药组合物 | |
CN104337989A (zh) | 一种含鹅不食草和乳香的治疗痛风的中药组合物 | |
CN110478416B (zh) | 治疗风湿性类风湿性关节炎的组合物及其制备方法和应用 | |
CN105521332A (zh) | 治疗肛裂的中药组合物及其制备方法和应用 | |
CN112618626A (zh) | 一种治疗带状疱疹的中药喷雾剂及其制备方法 | |
CN105362382A (zh) | 一种治疗复发性口腔溃疡中药组合物及其应用 | |
CN103908542B (zh) | 一种治疗类风湿性关节炎的复方制剂及其制备方法 | |
CN101647981B (zh) | 一种治疗血虚风燥型牛皮癣的药物 | |
CN100571725C (zh) | 一种治疗坐骨神经痛的中药制剂 | |
CN104173830A (zh) | 冬季感冒高烧解表和里药剂及制备方法 | |
CN102935139A (zh) | 治疗家畜慢性胃肠炎的复方蜂胶组合物及其制备方法 | |
CN102652768A (zh) | 一种舒筋活络、活血散瘀的药物组合物 | |
CN102940806B (zh) | 一种治疗高血脂的中药组合物 | |
CN107510765A (zh) | 一种治疗痰瘀痹络型风湿痹症的中药组合物及其制备方法 | |
CN104998189A (zh) | 一种治疗风热乘脾型小儿口疮的中药散剂及其制备方法 | |
CN101028445A (zh) | 一种治疗鱼鳞病的中成药 | |
CN106038905A (zh) | 一种麻醉止痛药物及其制备方法 | |
CN104906352A (zh) | 一种治疗虚火上炎型小儿口疮的中药药液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: LI BAOJI Free format text: FORMER OWNER: ZHAI FENG Effective date: 20150416 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Baoji Inventor before: Di Feng |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 043400 LINFEN, SHAANXI PROVINCE TO: 030024 TAIYUAN, SHAANXI PROVINCE Free format text: CORRECT: INVENTOR; FROM: ZHAI FENG TO: LI BAOJI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150416 Address after: 030024 No. 19 West Main Street, Wan Berlin District, Shanxi, Taiyuan, Yingze Applicant after: Li Baoji Address before: 043400 Shanxi city of Linfen province Quwo County Street Applicant before: Di Feng |
|
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Zuo Zhenbai Inventor before: Li Baoji |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160920 Address after: 266000 Shandong city of Qingdao province Jiangsu City Road No. 16 Applicant after: Zuo Zhenbai Address before: 030024 No. 19 West Main Street, Wan Berlin District, Shanxi, Taiyuan, Yingze Applicant before: Li Baoji |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161123 Termination date: 20190430 |